Expression of matrix metalloproteinases (MMP-2 and -9) and their inhibitors (TIMP-1 and -2) in prostate cancer tissue

Prostate Cancer and Prostatic Diseases

Volumn 6, Issue 3, 2003, Pages 217-222

  Brehmer, Bernhard ^a   Biesterfeld, S ^a   Jakse, G ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

Extracellular matrix; Immunohistochemistry; Metalloproteinases; Prostatic neoplasm; Tissue inhibitor of metalloproteinases

Indexed keywords

GELATINASE A; GELATINASE B; MATRIX METALLOPROTEINASE; PARAFFIN; PROSTATE SPECIFIC ANTIGEN; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER TISSUE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME ANALYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; MEDICAL LITERATURE; METASTASIS POTENTIAL; MICROSCOPY; PALPATION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE EPITHELIUM; PROSTATECTOMY; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SCORING SYSTEM; UPREGULATION;

AGED; EPITHELIAL CELLS; HUMANS; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; NEOPLASM STAGING; PROSTATIC NEOPLASMS; PROTEASE INHIBITORS; STROMAL CELLS; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2;

EID: 0141837010     PISSN: 13657852     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.pcan.4500657     Document Type: Article

References (38)

1. Liotta LA, Rao CN, Barsky SH. Tumor invasion and the extracellular matrix. Lab Invest 1983; 49: 636-649.
2. Wysocki AB, Staiano CL, Grinnell F. Wound fluid from chronic leg ulcers contains elevated levels of metalloproteinases MMP-2 and MMP-9. J Invest Dermatol 1993; 101: 64-68.
3. Mikuni TY, Cheng YS. Metalloproteinases in endochondral bone formation: appearance of tissue inhibitor-resistant metalloproteinases. Arch Biochem Biophys 1987; 259: 576-588.
4. Huppertz B et al. Immunohistochemistry of matrix metalloproteinases (MMP), their substrates, and their inhibitors (TIMP) during trophoblast invasion in the human placenta. Cell Tissue Res 1998; 291: 133-148.
5. Murray GI. Matrix metalloproteinases: a multifunctional group of molecules. J Pathol 2001; 195: 135-137.
6. Ahrens D et al. Expression of matrix metalloproteinase 9 (96-kd gelatinase B) in human rheumatoid arthritis. Arthritis Rheum 1996; 39: 1576-1587.
7. Arthur MJ. Degradation of matrix proteins in liver fibrosis. Pathol Res Pract 1994; 190: 825-833.
8. Parsons SL et al. Matrix metalloproteinases [see comments]. Br J Surg 1997; 84: 160-166.
9. Docherty AJ, O'Connell J, Crabbe T, Angal S, Murphy G. The matrix metalloproteinases and their natural inhibitors: prospects for treating degenerative tissue diseases. Trends Biotechnol 1992; 10: 200-207.
10. Karakiulakis G et al. Increased type IV collagen-degrading activity in metastases originating from primary tumors of the human colon. Invasion Metastasis 1997; 17: 158-168.
11. Bachmeier BE, Nerlich AG, Lichtinghagen R, Sommerhoff CP. Matrix metalloproteinases (MMPs) in breast cancer cell lines of different tumorigenicity. Anticancer Res 2001; 21: 3821-3828.
12. Pagenstecher A et al. Distinct expression patterns and levels of enzymatic activity of matrix metalloproteinases and their inhibitors in primary brain tumors. J Neuropathol Exp Neurol 2001; 60: 598-612.
13. Wilson MJ et al. Expression of matrix metalloproteinase-2 and -9 and their inhibitors, tissue inhibitor of metalloproteinase-1 and -2, in primary cultures of human prostatic stromal and epithelial cells. J Cell Physiol 2002; 191: 208-216.
14. Varani J et al. Matrix metalloproteinases (MMPs) in fresh human prostate tumour tissue and organ-cultured prostate tissue: levels of collagenolytic and gelatinolytic MMPs are low, variable and different in fresh tissue versus organ-cultured tissue. Br J Cancer 2001; 84: 1076-1083.
15. Crawford HC, Matrisian LM. Mechanisms controlling the transcription of matrix metalloproteinase genes in normal and neoplastic cells. Enzyme Protein 1996; 49: 20-37.
16. Nagase H. Activation mechanisms of matrix metalloproteinases. Biol Chem 1997; 378: 151-160.
17. Bee A et al. Canine TIMP-2: purification, characterization and molecular detection [In Process Citation]. Vet J 2000; 160: 126-134.
18. Liu YE et al. Preparation and characterization of recombinant tissue inhibitor of metalloproteinase 4 (TIMP-4). J Biol Chem 1997; 272: 20479-20483.
19. Schaefer L et al. Differential regulation of glomerular gelatinase B (MMP-9) and tissue inhibitor of metalloproteinase-1 (TIMP-1) in obese Zucker rats. Diabetologia 1997; 40(9): 1035-1043.
20. Kodate M et al. Expression of matrix metalloproteinase (gelatinase) in T1 adenocarcinoma of the lung. Pathol Int 1997; 47: 461-469.
21. Gallegos NC et al. The distribution of matrix metalloproteinases and tissue inhibitor of metalloproteinases in colorectal cancer. Surg Oncol 1995; 4: 111-119.
22. Polette M et al. Detection and localization of mRNAs encoding matrix metalloproteinases and their tissue inhibitor in human breast pathology. Invasion Metastasis 1993; 13: 31-37.
23. Boag AH, Young ID. Increased expression of the 72-kd type IV collagenase in prostatic adenocarcinoma. Demonstration by immunohistochemistry and in situ hybridization. Am J Pathol 1994; 144: 585-591.
24. Schmid HP, McNeal JE. An abbreviated standard procedure for accurate tumor volume estimation in prostate cancer. Am J Surg Pathol 1992; 16: 184-191.
25. Davies B et al. Levels of matrix metalloproteases in bladder cancer correlate with tumor grade and invasion. Cancer Res 1993; 53: 5365-5369.
26. Poulsom R et al. Stromal expression of 72 kda type IV collagenase (MMP-2) and TIMP-2 mRNAs in colorectal neoplasia. Am J Pathol 1992; 141: 389-396.
27. Asai M et al. Differential regulation of MMP-9 and TIMP-2 expression in malignant melanoma developed in metallothionein/RET transgenic mice. Jpn J Cancer Res 1999; 90: 86-92.
28. Stearns ME, Wang M, Stearns M. IL-10 blocks collagen IV invasion by 'invasion stimulating factor' activated PC-3 ML cells: upregulation of TIMP-1 expression. Oncol Res 1995; 7: 157-163.
29. DeClerck YA et al. Tissue inhibitors of metalloproteinases: role in tumor progression. Contrib Nephrol 1994; 107: 108-115.
30. Albini A, Melchiori A, Sand L, Liotta LA, Brown PD, Stetler SW. Tumor cell invasion inhibited by TIMP-2 [see comments]. J Natl Cancer Inst 1991; 83: 775-779.
31. Bramhall SR, Neoptolemos JP, Stamp GW, Lemoine NR. Imbalance of expression of matrix metalloproteinases (MMPs) and tissue inhibitors of the matrix metalloproteinases (TIMPs) in human pancreatic carcinoma. J Pathol 1997; 182: 347-355.
32. Kinoshita T et al. TIMP-2 promotes activation of progelatinase A by membrane-type 1 matrix metalloproteinase immobilized on agarose beads. J Biol Chem 1998; 273: 16098-16103.
33. Caterina JJ et al. Inactivating mutation of the mouse tissue inhibitor of metalloproteinases-2(Timp-2) gene alters proMMP-2 activation. J Biol Chem 2000; 275: 26416-26422.
34. Sakata K, Shigemasa K, Nagai N, Ohama K. Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors (TIMP-1, TIMP-2) in common epithelial tumors of the ovary [In Process Citation]. Int J Oncol 2000; 17: 673-681.
35. Cooner WH et al. Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen. J Urol 1990; 143: 1146-1152.
36. Geary ES, Stamey TA. Pathological characteristics and prognosis of nonpalpable and palpable prostate cancers with a Hybritech prostate specific antigen of 4-10 ng/ml [see comments]. J Urol 1996; 156: 1056-1058.
37. Epstein JI, Walsh PC, Brendler CB. Radical prostatectomy for impalpable prostate cancer: the Johns Hopkins experience with tumors found on transurethral resection (stages T1A and T1B) and on needle biopsy (stage T1C) [see comments]. J Urol 1994; 152: 1721-1729.
38. Agren MS et al. Matrix metalloproteinase 9 level predicts optimal collagen deposition during early wound repair in humans. Br J Surg 1998; 85: 68-71.